logo

Axovant Sciences Ltd. (AXON)



Trade AXON now with
  Date
  Headline
7/8/2018 8:45:41 PM Axovant Announces Licensing Agreement For AXO-AAV-OPMD Program For Treatment Of Oculopharyngeal Muscular Dystrophy
6/6/2018 2:15:05 AM Oxford BioMedica Enters Exclusive Worldwide Licensing Agreement With Axovant
6/6/2018 2:05:50 AM Axovant Sciences Licenses Exclusive Worldwide Rights To Develop OXB-102, Now AXO-Lenti-PD, From Oxford BioMedica
2/12/2018 7:02:11 AM Axovant Sciences CEO David Hung Resigns To Pursue Other Opportunities
1/8/2018 7:09:24 AM Axovant: Intepirdine Did Not Meet Primary Efficacy Endpoints In Phase 2b HEADWAY, Pilot Phase 2 Gait And Balance Studies